Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hedley Griffiths

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
International Journal of Rheumatic Diseases|October 18, 2013
A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practiceDave Nicholls, Jane Zochling, Anthony Boers, et al.
The Journal of Rheumatology|December 3, 2019
Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis DatasetPeter Youssef, Bruno Marcal, Peter Button, et al.
International Journal of Rheumatic Diseases|February 17, 2017
Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT studyPaul Bird, Dave Nicholls, Rina Barrett, et al.
The Journal of Rheumatology|July 3, 2015
Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational StudyGeoffrey Littlejohn, Lynden Roberts, Paul Bird, et al.
Clinical Rheumatology|November 26, 2021
Prevalence of sleep disturbance and the association between poor disease control in people with ankylosing spondylitis within the Australian clinical setting (ASLEEP study): a real-world observational study using the OPAL datasetKathleen Tymms, Belinda E Butcher, Tracey L Sletten, et al.
International Journal of Rheumatology|June 21, 2017
The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology PracticeLynden Roberts, Kathleen Tymms, Julien de Jager, et al.
Arthritis Care & Research|August 29, 2013
Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activityKathleen Tymms, Jane Zochling, James Scott, et al.
International Journal of Rheumatic Diseases|July 22, 2017
Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian studyKathleen Tymms, Ayano Kelly, Paul Bird, et al.
The Journal of Rheumatology|January 17, 2013
The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritisPaul Bird, Hedley Griffiths, Kathleen Tymms, et al.
Clinical Rheumatology|April 19, 2018
Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitorsKathleen Tymms, Geoff Littlejohn, Hedley Griffiths, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
International Journal of Rheumatic Diseases|October 18, 2013
A retrospective chart review of the use of rituximab for the treatment of rheumatoid arthritis in Australian rheumatology practiceDave Nicholls, Jane Zochling, Anthony Boers, et al.
The Journal of Rheumatology|December 3, 2019
Reasons for Biologic and Targeted Synthetic Disease-modifying Antirheumatic Drug Cessation and Persistence of Second-line Treatment in a Rheumatoid Arthritis DatasetPeter Youssef, Bruno Marcal, Peter Button, et al.
International Journal of Rheumatic Diseases|February 17, 2017
Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT studyPaul Bird, Dave Nicholls, Rina Barrett, et al.
The Journal of Rheumatology|July 3, 2015
Patients with Rheumatoid Arthritis in the Australian OPAL Cohort Show Significant Improvement in Disease Activity over 5 Years: A Multicenter Observational StudyGeoffrey Littlejohn, Lynden Roberts, Paul Bird, et al.
Clinical Rheumatology|November 26, 2021
Prevalence of sleep disturbance and the association between poor disease control in people with ankylosing spondylitis within the Australian clinical setting (ASLEEP study): a real-world observational study using the OPAL datasetKathleen Tymms, Belinda E Butcher, Tracey L Sletten, et al.
International Journal of Rheumatology|June 21, 2017
The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology PracticeLynden Roberts, Kathleen Tymms, Julien de Jager, et al.
Arthritis Care & Research|August 29, 2013
Barriers to optimal disease control for rheumatoid arthritis patients with moderate and high disease activityKathleen Tymms, Jane Zochling, James Scott, et al.
International Journal of Rheumatic Diseases|July 22, 2017
Psoriatic arthritis treatment regimens, therapy duration and reasons for cessation in the biologics era: a multi-centre Australian studyKathleen Tymms, Ayano Kelly, Paul Bird, et al.
The Journal of Rheumatology|January 17, 2013
The SMILE study -- safety of methotrexate in combination with leflunomide in rheumatoid arthritisPaul Bird, Hedley Griffiths, Kathleen Tymms, et al.
Clinical Rheumatology|April 19, 2018
Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitorsKathleen Tymms, Geoff Littlejohn, Hedley Griffiths, et al.
Pageof 3